Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

NCT00088504 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

315

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
Hepatitis

Interventions

DRUG: Merimepodib
DRUG: PEG-Interferon-alpha 2a (Pegasys®)
DRUG: Ribavirin (Copegus®)

Sponsor

Vertex Pharmaceuticals Incorporated